Is Relay Therapeutics, Inc. (RLAY) a Buy, Sell, or Hold?
NASDAQ : RLAY
Relay Therapeutics, Inc.
$18.44 USD
-$0.65 (-3.4%)
- Volume
- 2.04M
- Average Volume
- 4.14M
- Market Capitalization
- $3.23B
- P/E Ratio
- -11.75
- Dividend Yield
- 0.00%
- Price Target
- $26.50
- Year High
- $20.79
- Year Low
- $3.03
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $22.13
Company Overview
NASDAQ
Sanjiv K. Patel
Biotechnology
Healthcare
RLAY
259
US
USD
Liquidity Metrics
0.05
22.13
22.13
6.88
0.00
Sales & Valuation
$15.36M
302.27
5.16
-15.12
-1.19
Profitability
-$1.61
-$276.48M
-2554.14%
-2554.14%
-43.94%
-38.98%
P/E Metrics
-11.75
-0.31
-0.31
Analyst Price Target & Rating
$26.50
$31.00
$18.00
2/5
15 Analysts
-30.42%
Financial Health Scores
30.53
3/9
$628.71M
$699.61M
$57.43M
-$272.7M
Key Metrics (TTM)
$3.05B
286.06
-11.17
22.13
-43.94%
-44.00%
-8.22%
-6.61%
-11 days
Company Executives
| Name | Title |
|---|---|
| Soo-Yeun Lim | Senior Vice President & General Counsel |
| David Elliot Shaw | Founder |
| Matthew Jacobson | Founder |
| Dorothee Kern | Founder |
| Donald A. Bergstrom | President of Research & Development |
| Mark Murcko | Founder & Independent Director |
| Sanjiv K. Patel MBBS | Chief Executive Officer, President & Director |
| Jim Watters | Chief Scientific Officer |
| Peter Rahmer | Chief Corporate Development Officer |
| Thomas Catinazzo | Chief Financial Officer |
Poll Results
No votes yet today — be the first to share your view!
About Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology ... region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
2026-07-23 09:05:00
/PRNewswire/ -- For years, the promise of artificial intelligence in drug discovery has been easy to describe and hard to monetize. Plenty of companies can
Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past Year
2026-06-29 19:52:02
Thomas Catinazzo sold 187,163 shares of Common Stock for $3.18 million on June 22, 2026, at a weighted average price of around $16.97 per share. This transaction reduced his direct Common Stock holdings by 51.33%, leaving 177,461 shares directly held after the sale.
2026-06-08 12:58:31
Relay Therapeutics, Inc. (RLAY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June
2026-05-27 16:05:00
CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in June: 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 12:45 p.m.
Is Relay Therapeutics a Buy After Promising Trial Results?
2026-05-22 17:30:00
Relay had its initial public offering in 2020. The company's lead therapy is being tested for the treatment of vascular disorders and cancers.
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
2026-05-20 20:21:22
CAMBRIDGE, Mass. , May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today the pricing of an underwritten public offering of 22,916,667 shares of its common stock at a public offering price of $12.
Relay Therapeutics Announces Pricing of Public Offering of Common Stock
2026-05-20 20:21:00
CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today the pricing of an underwritten public offering of 22,916,667 shares of its common stock at a public offering price of $12.00 per share. Relay Therapeutics also granted the underwriters a 30-day option to purchase up to an additional 3,437,500 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $275 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Relay Therapeutics.
Why Relay Therapeutics Stock Popped on Wednesday
2026-05-20 19:01:49
This was aided by a pair of bullish analyst updates. The two pundits raised their price targets and maintained their buy ratings.
Frequently Asked Questions
-
What is the current Relay Therapeutics, Inc. (RLAY) stock price?
-
Relay Therapeutics, Inc.(NASDAQ:RLAY) stock price is $18.44 in the last trading session. During the trading session, RLAY stock reached the peak price of $20.79 while $3.025 was the lowest point it dropped to. The percentage change in RLAY stock occurred in the recent session was --3.4% while the dollar amount for the price change in RLAY stock was -$0.65.
-
RLAY's industry and sector of operation?
-
The NASDAQ listed RLAY is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of RLAY?
-
Soo-Yeun Lim | Senior Vice President & General Counsel
David Elliot Shaw | Founder
Matthew Jacobson | Founder
Dorothee Kern | Founder
Donald A. Bergstrom | President of Research & Development -
How many employees does RLAY have?
-
Number of RLAY employees currently stands at 259. RLAY operates from 60 Hampshire Street, Cambridge, MA 02139, US.
-
Link for RLAY official website?
-
Official Website of RLAY is: https://www.relaytx.com
-
How do I contact RLAY?
-
RLAY could be contacted at phone #617 370 8837 and can also be accessed through its website. RLAY operates from 60 Hampshire Street, Cambridge, MA 02139, US.
-
How many shares of RLAY are traded daily?
-
The average number of RLAY shares traded daily for last 3 months was 4.14M.
-
What is the market cap of RLAY currently?
-
The market value of RLAY currently stands at $3.23B with its latest stock price at $18.44